Morgan Stanley Hopes for Some Retail Therapy for Humana
In a report published Thursday, Morgan Stanley analyst Andrew Schenker reiterated an Equal-Weight rating on Humana (NYSE: HUM).
In the report, Morgan Stanley noted, “HUM maintained its 2014 EPS outlook of $7.25 to $7.75, but increased its Medicare Advantage, Part D, and commercial individual enrollment outlook on the heels of 4Q. We have lowered our FY14 EPS by $0.05 to $7.70, which reflects higher revenue from new lives, but a lower overall pre-tax margin.”
Humana closed on Wednesday at $95.71.
Latest Ratings for HUM
|Jan 2017||PiperJaffray||Initiates Coverage On||Overweight|
|Dec 2016||Cantor Fitzgerald||Downgrades||Buy||Hold|
|Nov 2016||Credit Suisse||Upgrades||Neutral||Outperform|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.